MINOCIN
What it isTetracycline inhibiting the 30S ribosomal subunit; acne, MRSA skin infection and rosacea.
Why this oneThe most lipophilic tetracycline, so it penetrates sebaceous glands and the CNS better than doxycycline.
What limits itVestibular effects, and irreversible blue-gray skin and scleral pigmentation with prolonged use. Drug-induced lupus.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Susceptible infections (general) | Adult | 200 mg ×1 | 100 mg BID (q12h) | 200 mg/24 h |
| Susceptible infections | Peds >8 yr | 4 mg/kg ×1 | 2 mg/kg q12h | usual adult dose |
| Uncomplicated gonococcal urethritis (men) | Adult | 100 mg BID ×5 days | ||
| Other gonococcal infections (men) | Adult | 200 mg ×1 then 100 mg q12h ≥4 days | ||
| Syphilis | Adult | usual dose over 10–15 days | ||
| Meningococcal carrier state | Adult | 100 mg q12h ×5 days | ||
| Chlamydia/Ureaplasma (urethral/endocervical/rectal) | Adult | 100 mg q12h ≥7 days | ||
| Mycobacterium marinum | Adult | 100 mg q12h ×6–8 wk |
Renal Do not exceed 200 mg/24 h; monitor BUN/creatinine (antianabolic effect); specific adjustment not characterized
Hepatic Undefined
Total daily dose should not exceed 200 mg in 24 h
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskVestibular effects and skin hyperpigmentation
Cost, est. cash$300–$2,500/month
Generic entry1990
Legacy pregnancy categoryD
Defining liabilityAllergy, gastrointestinal effects and agent-specific renal, hepatic, hematologic or interaction risks.

Open Minocycline in the interactive console ↗
